Japan okays GSK’s Sotrovimab for treating Covid-19 patients. (Reuters)
<p>
Japan has approved GlaxoSmithKline and Vir Biotechnology&#39;s Sotrovimab medicine as an antibody treatment for coronavirus, Health Minister Norihisa Tamura said on Monday.</p>
<p>
The antibody treatment is for mild to moderate COVID-19 cases which do not require oxygen supplementation, GSK said when it applied for fast-track approval this month.</p>
<p>
Sotrovimab has already been granted an emergency use approval by the FDA to facilitate the availability and use of this investigational monoclonal antibody for the treatment of COVID-19 in the U.S.</p>
<p>
GSK had claimed interim study results demonstrated an 85% reduction in hospitalisation for more than 24 hours or death in those receiving sotrovimab compared to placebo, the primary endpoint of the trial</p>
US President Joe Biden has directed his Trade Representative to increase tariffs on USD 18…
A delegation consisting of 15 officials of the Sri Lankan Supreme Court successfully completed a…
India's smartphone market shipped 34 million smartphone units in the first quarter of 2024. It…
In a step towards bolstering maritime cooperation, the 16th Indian Navy-Australian Navy Staff Talks concluded…
After several days of intense protests and violence which led to the death of three…
In a concerted effort to strengthen ties and collaborate on development initiatives in Africa, the…